These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19480465)

  • 1. Improving compliance with interferon-beta therapy in patients with multiple sclerosis.
    Portaccio E; Amato MP
    CNS Drugs; 2009; 23(6):453-62. PubMed ID: 19480465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rebif new formulation story: it's not trials and error.
    Jaber A; Driebergen R; Giovannoni G; Schellekens H; Simsarian J; Antonelli M
    Drugs R D; 2007; 8(6):335-48. PubMed ID: 17963425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
    BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment and dose optimisation BENEFIT and BEYOND.
    Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
    Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K;
    J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
    Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
    BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
    Arnason BG
    J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.